drugset / Trial / NCT00579020

A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates

NCT00579020

Phase 2 Terminated 144 enrolled Alcon Research
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to determine whether Moxidex ophthalmic solution is safe and effective in treating marginal corneal infiltrates.

Timeline

Start
2007-12
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexamethasone Small molecule 0.1 % Topical
Comparator Moxifloxacin Small molecule 0.5 % Topical
Subject Moxifloxacin/dexamethasone phosphate Unknown Topical

Indications